IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by the desire to strengthen this relationship, the two entities have signed a partnership agreement (Master Research Service Agreement), making it a long-term partnership. This agreement will facilitate and accelerate exchanges between the two teams, enabling them to offer integrated, agile and efficient solutions for the healthcare industry in France.
Created in 2012 from the French Technological Research Institutes (IRT) initiative, BIOASTER is a non-profit foundation developing a unique and innovative technological model to meet the new challenges of microbiology and infectious diseases. Its aim is to bring together academia and industry to develop and execute collaborative research projects with high impact for patients.
As part of its ongoing development, BIOASTER aims to work with benchmark partners who are leaders in their fields, enabling the IRT to offer an integrated range of technologies tailored to the needs of its research projects, in terms of both variety and volume.
"IntegraGen has demonstrated its ability to respond rapidly to our sequencing needs and to deliver quality data in the shortest possible time. At BIOASTER, we are delighted to strengthen our collaboration with an expert team in whom we have full confidence."Adrien Saliou, B.Eng, PhD, Genomics and Transcriptomics Team Leader, OMICS Hub, BIOASTER.
"Our collaboration with BIOASTER is based on the responsiveness, communication and professionalism of our two teams. It is an honor for IntegraGen to contribute to the challenge of understanding the mechanisms of biological systems and combating infectious agents alongside a key player in microbiology.,"Emmanuel Martin, Chief Operating Officer of the OncoDNA Group.
Leave a Reply